Vandetanib Active in RET-rearranged Advanced NSCLC
Vandetanib demonstrates antitumor activity among patients with advanced RET-rearranged non-small cell lung cancer (NSCLC).
Vandetanib demonstrates antitumor activity among patients with advanced RET-rearranged non-small cell lung cancer (NSCLC).
Prexasertib demonstrates promising activity in patients with BRCA wild type sporadic high-grade serous ovarian cancer.
Treatment with selinexor is active in patients with heavily pretreated patients with metastatic ovarian or endometrial cancer.
Researchers can use metastasis-free survival as a surrogate end point for overall survival in clinical trials evaluating patients with localized prostate cancer.
Adding chemoradiotherapy prior to surgery improves survival versus surgery alone in patients with locally advanced esophageal squamous cell carcinoma (SCC).
Lurbinectedin induces DNA double-strand breaks, and regulates the tumor microenvironment.
MYL-1401H is equivalent in efficacy to pegfilgrastim for the prevention of chemotherapy-induced neutropenia among patients with breast cancer.
In contrast with a 3 mg/kg dose, ipilimumab monotherapy at a dose of 10 mg/kg is associated with improved overall survival.